Compare NMIH & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NMIH | LQDA |
|---|---|---|
| Founded | 2011 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.1B |
| IPO Year | 2013 | 2020 |
| Metric | NMIH | LQDA |
|---|---|---|
| Price | $37.26 | $36.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | ★ $43.00 | $40.36 |
| AVG Volume (30 Days) | 343.9K | ★ 1.5M |
| Earning Date | 04-28-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 11.06 | ★ 51.81 |
| EPS | ★ 4.92 | N/A |
| Revenue | ★ $706,440,000.00 | $158,320,000.00 |
| Revenue This Year | N/A | $208.46 |
| Revenue Next Year | $4.34 | $27.44 |
| P/E Ratio | $7.56 | ★ N/A |
| Revenue Growth | 8.52 | ★ 1031.18 |
| 52 Week Low | $32.71 | $11.26 |
| 52 Week High | $43.20 | $46.67 |
| Indicator | NMIH | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 38.20 | 51.94 |
| Support Level | $36.78 | $30.48 |
| Resistance Level | $37.66 | $39.19 |
| Average True Range (ATR) | 0.74 | 2.15 |
| MACD | -0.16 | 0.44 |
| Stochastic Oscillator | 25.54 | 72.92 |
NMI Holdings Inc through its subsidiaries provides private mortgage guaranty insurance. The company offers mortgage insurance, reinsurance on loans, and outsourced loan review services to mortgage loan originators. It serves national and regional mortgage banks, money center banks, credit unions, community banks, builder-owned mortgage lenders, Internet-sourced lenders, and other non-bank lenders. It protects lenders and investors from default-related losses on a portion of the unpaid principal balance of a covered mortgage.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.